KRAS and pancreatic ductal adenocarcinoma: KRas has been implicated in difficult-to-treat cancers such as pancreatic ductal adenocarcinoma (PDAC) and has therefore been thoroughly studied [47, 47, 48, 48, 49, 49–55, 55, 56, 56–60, 69, 70].